Guntram Schernthaner

List of Publications by Citations

Source: https://exaly.com/author-pdf/8328765/guntram-schernthaner-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44 papers	5,780 citations	20 h-index	54 g-index
54 ext. papers	6,607 ext. citations	8.3 avg, IF	5.12 L-index

#	Paper	IF	Citations
44	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet, The*, **2005**, 366, 1279-89	40	3186
43	Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. *Diabetes Care*, **2013**, 36, 2508-15	14.6	375
42	Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). *Stroke*, **2007**, 38, 865-73	6.7	374
41	Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 3027-37	12.7	280
40	Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. *Journal of the American Medical Directors Association*, **2012**, 13, 497-502	5.9	263
39	Hypoglycemia and cardiovascular risks. *Diabetes Care*, **2011**, 34 Suppl 2, S132-7	14.6	249
38	Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. *Lancet, The*, **2012**, 379, 2270-8	40	125
37	Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. *Diabetes Care*, **2007**, 30, 1834-9	14.6	120
36	Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 182-7	12.7	107
35	Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. *Diabetes Care*, **2013**, 36 Suppl 2, S155-61	14.6	68
34	Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractant-protein-1 in morbid obesity. *Obesity Surgery*, **2006**, 16, 709-15	3.7	68
33	YKL-40 is elevated in morbidly obese patients and declines after weight loss. *Obesity Surgery*, **2009**, 19, 1557-63	3.7	61
32	Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery. *Obesity Surgery*, **2009**, 19, 29-35	3.7	50
31	Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery. *Obesity Surgery*, **2018**, 28, 643-648	3.7	47
30	Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. *Diabetologia*, **2018**, 61, 1503-1516	10.3	40
29	The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. *Diabetes and Vascular Disease Research*, **2014**, 11, 306-23	3.3	40
28	Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. *Cardiovascular Diabetology*, **2015**, 14, 116	8.7	36

27	EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. *Clinical Therapeutics*, **2016**, 38, 1288-1298	3.5	24
26	Achieving glycemic control in patients with type 2 diabetes and renal impairment. *Acta Diabetologica*, **2013**, 50, 283-91	3.9	19
25	Cure of type 2 diabetes by metabolic surgery? A critical analysis of the evidence in 2010. *Diabetes Care*, **2011**, 34 Suppl 2, S355-60	14.6	19
24	Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS. *Diabetes Care*, **2016**, 39 Suppl 2, S210-8	14.6	17
23	The right place for metformin today. *Diabetes Research and Clinical Practice*, **2020**, 159, 107946	7.4	16
22	Frequency of Hypoglycaemia after Different Bariatric Surgical Procedures. *Obesity Facts*, **2019**, 12, 397-406	5.1	13
21	Therapy: Risk of metformin use in patients with T2DM and advanced CKD. *Nature Reviews Endocrinology*, **2015**, 11, 697-9	15.2	12
20	Kidney disease in diabetology: lessons from 2007. *Nephrology Dialysis Transplantation*, **2008**, 23, 1112-5	4.3	12
19	Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?. *Cardiovascular Diabetology*, **2018**, 17, 145	8.7	11
18	Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). *Cardiovascular Diabetology*, **2017**, 16, 137	8.7	9
17	Kidney disease in diabetology: lessons from 2010. *Nephrology Dialysis Transplantation*, **2011**, 26, 454-7	4.3	8
16	Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. *Postgraduate Medicine*, **2016**, 128, 725-730	3.7	8
15	SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class. *BMC Endocrine Disorders*, **2019**, 19, 64	3.3	7
14	Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy?. *Nature Clinical Practice Nephrology*, **2008**, 4, 656-7		7
13	Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. *Therapeutics and Clinical Risk Management*, **2017**, 13, 69-79	2.9	6
12	Kidney disease in diabetology: lessons from 2008. *Nephrology Dialysis Transplantation*, **2009**, 24, 396-9	4.3	6
11	Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs. *Cardiovascular Diabetology*, **2019**, 18, 115	8.7	5
10	Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 251-252	18.1	5

9	Sodium-glucose linked transporter-2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1024-1034	6.7	4
8	Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure.. *Metabolism: Clinical and Experimental*, **2022**, 130, 155160	12.7	3
7	Metformin From Devil to Angel **2007**, 77-86		3
6	CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. *Diabetes Research and Clinical Practice*, **2019**, 153, 30-40	7.4	2
5	The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?. *Cardiovascular Diabetology*, **2021**, 20, 198	8.7	2
4	Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9). *Diabetes and Metabolism Journal*, **2021**, 45, 615-616	5	1
3	GLP-1 receptor agonists and cardiovascular risk in routine clinical practice. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 78-80	18.1	1
2	Hypertension and Diabetes **2007**, 417-436		0
1	Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action. *Expert Review of Endocrinology and Metabolism*, **2016**, 11, 281-296	4.1	